RECOMBINANT VACCINE FOR LYME DISEASE

描述(改编自申请人的摘要)：免疫接种 伯氏疏螺旋体外表面蛋白A或OSPC 诱导对后续攻击的保护性免疫力 B.burgdorferi，从中衍生出OSP。然而，Ospa和 Ospc是异质性的，对一种毒株的保护作用不是 必须防止受到其他菌株的挑战。这个 研究人员建议开发一种具有董事会范围的多价疫苗 是一种保护。在初步研究中，调查人员已经 构建了表达OspA和OspA组成的蛋白质的嵌合基因 部分疏螺旋体菌株的OspC片段。这些嵌合基因 将在大肠杆菌中以无脂蛋白嵌合体的形式过度表达。 非脂蛋白质的产生浓度比 脂化蛋白质。这些化合物中Cys残基的侧链 重组嵌合体将被化学修饰以引入脂质 膜锚。在第二阶段，合成脂蛋白嵌合体 将分别和组合在动物模型中进行测试，以 评估它们预防一系列疏螺旋体感染的效果 菌株。调查人员预计，这将产生第二个 将提供更长免疫期限的新一代人类疫苗 与目前处于临床试验中的候选疫苗相比，有更好的保护作用。 建议的商业应用：不可用。

DESCRIPTION (Adapted from the applicant's abstract): Immunization with either Borrelia burgdorferi outer surface protein (Osp) A or OspC induces protective immunity to subsequent challenge with the strain of B. burgdorferi from which the Osp's were derived. However, OspA and OspC are heterogeneous and protection against one strain does not necessarily protect against challenge with other strains. The investigators propose to develop a polyvalent vaccine with a board range of protection. In preliminary studies, the investigators have constructed chimeric genes that express proteins comprised of OspA and OspC segments from selected strains of Borrelia. These chimeric genes will be overexpressed in E. coli as unlipidated protein chimers. Unlipidated proteins can be produced at much higher concentrations than lipidated proteins. The side-chains of Cys residues in these recombinant chimers will be chemically modified to introduce lipid membrane anchors. During Phase II, the synthetic lipoprotein chimers will be tested in animal models, separately and in combination, to assess their efficacy in preventing infection with an array of Borrelia strains. The investigators expect that this will produce a second generation human vaccine that will provide a longer duration of immune protection compared to vaccine candidates currently in clinical trials. PROPOSED COMMERCIAL APPLICATION: Not available.